Literature DB >> 18687797

Genetic counseling and testing for common hereditary breast cancer syndromes: a paper from the 2007 William Beaumont hospital symposium on molecular pathology.

Dawn C Allain1.   

Abstract

Throughout the past 15 years, the identification of several genes associated with hereditary breast cancer has fueled the growth of clinical genetic counseling and testing services. In addition, increased knowledge of the genetic and molecular pathways of the known hereditary breast cancer genes, as well as an increased understanding of the impact of testing on individuals has added to the ability to identify, manage, and provide psychosocial support for mutation carriers. This review provides an overview of the clinical features, cancer risks, causative genes, and management for hereditary breast and ovarian cancer syndrome, Cowden syndrome, and Li-Fraumeni syndrome. This article summarizes the genetic counseling process and genetic test result interpretation, including a review of the key elements involved in the provision of risk assessment and informed consent, as well as a review of the risks, benefits, and limitations of cancer susceptibility genetic testing.

Entities:  

Mesh:

Year:  2008        PMID: 18687797      PMCID: PMC2518733          DOI: 10.2353/jmoldx.2008.070161

Source DB:  PubMed          Journal:  J Mol Diagn        ISSN: 1525-1578            Impact factor:   5.568


  156 in total

1.  Variants of uncertain clinical significance as a result of BRCA1/2 testing: impact of an ambiguous breast cancer risk message.

Authors:  Sandra van Dijk; Christi J van Asperen; Catharina E Jacobi; Geraldine R Vink; Aad Tibben; Martijn H Breuning; Wilma Otten
Journal:  Genet Test       Date:  2004

Review 2.  A patient with 17 primary tumours and a germ line mutation in TP53: tumour induction by adjuvant therapy?

Authors:  C Nutting; R S Camplejohn; R Gilchrist; D Tait; P Blake; G Knee; W Q Yao; G Ross; C Fisher; R Eeles
Journal:  Clin Oncol (R Coll Radiol)       Date:  2000       Impact factor: 4.126

3.  A high proportion of novel mutations in BRCA1 with strong founder effects among Dutch and Belgian hereditary breast and ovarian cancer families.

Authors:  T Peelen; M van Vliet; A Petrij-Bosch; R Mieremet; C Szabo; A M van den Ouweland; F Hogervorst; R Brohet; M J Ligtenberg; E Teugels; R van der Luijt; A H van der Hout; J J Gille; G Pals; I Jedema; R Olmer; I van Leeuwen; B Newman; M Plandsoen; M van der Est; G Brink; S Hageman; P J Arts; M M Bakker; P Devilee
Journal:  Am J Hum Genet       Date:  1997-05       Impact factor: 11.025

4.  Appropriateness of breast-conserving treatment of breast carcinoma in women with germline mutations in BRCA1 or BRCA2: a clinic-based series.

Authors:  Mark Robson; Tiffany Svahn; Beryl McCormick; Patrick Borgen; Clifford A Hudis; Larry Norton; Kenneth Offit
Journal:  Cancer       Date:  2005-01-01       Impact factor: 6.860

5.  Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: an international case-control study.

Authors:  Andrea Eisen; Jan Lubinski; Jan Klijn; Pal Moller; Henry T Lynch; Kenneth Offit; Barbara Weber; Tim Rebbeck; Susan L Neuhausen; Parviz Ghadirian; William D Foulkes; Ruth Gershoni-Baruch; Eitan Friedman; Gadi Rennert; Teresa Wagner; Claudine Isaacs; Charmaine Kim-Sing; Peter Ainsworth; Ping Sun; Steven A Narod
Journal:  J Clin Oncol       Date:  2005-10-20       Impact factor: 44.544

Review 6.  Li-Fraumeni syndrome--a molecular and clinical review.

Authors:  J M Varley; D G Evans; J M Birch
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

7.  Cancer Incidence in BRCA1 mutation carriers.

Authors:  Deborah Thompson; Douglas F Easton
Journal:  J Natl Cancer Inst       Date:  2002-09-18       Impact factor: 13.506

8.  Gynecologic surgeries and risk of ovarian cancer in women with BRCA1 and BRCA2 Ashkenazi founder mutations: an Israeli population-based case-control study.

Authors:  Joni L Rutter; Sholom Wacholder; Angela Chetrit; Flora Lubin; Joseph Menczer; Sarah Ebbers; Margaret A Tucker; Jeffery P Struewing; Patricia Hartge
Journal:  J Natl Cancer Inst       Date:  2003-07-16       Impact factor: 13.506

9.  Histopathologic features of genetically determined ovarian cancer.

Authors:  P A Shaw; J R McLaughlin; R P Zweemer; S A Narod; H Risch; R H M Verheijen; A Ryan; F H Menko; P Kenemans; I J Jacobs
Journal:  Int J Gynecol Pathol       Date:  2002-10       Impact factor: 2.762

Review 10.  Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis.

Authors:  M S Greenblatt; W P Bennett; M Hollstein; C C Harris
Journal:  Cancer Res       Date:  1994-09-15       Impact factor: 12.701

View more
  8 in total

1.  Who is being referred to cancer genetic counseling? Characteristics of counselees and their referral.

Authors:  E van Riel; S van Dulmen; M G E M Ausems
Journal:  J Community Genet       Date:  2012-03-17

2.  Social isolation reduces mammary development, tumor incidence, and expression of epigenetic regulators in wild-type and p53-heterozygotic mice.

Authors:  Nina S Hasen; Kathleen A O'Leary; Anthony P Auger; Linda A Schuler
Journal:  Cancer Prev Res (Phila)       Date:  2010-04-27

3.  Second primary cancers in long-term survivors of glioblastoma.

Authors:  Jung-Young Kim; Jennifer G Jackman; Sarah Woodring; Frances McSherry; James E Herndon; Annick Desjardins; Henry S Friedman; Katherine B Peters
Journal:  Neurooncol Pract       Date:  2019-02-04

4.  Prevalence of the BRCA1 founder mutation c.5266dupin Brazilian individuals at-risk for the hereditary breast and ovarian cancer syndrome.

Authors:  Ingrid P Ewald; Patrícia Izetti; Fernando R Vargas; Miguel Am Moreira; Aline S Moreira; Carlos A Moreira-Filho; Danielle R Cunha; Sara Hamaguchi; Suzi A Camey; Aishameriane Schmidt; Maira Caleffi; Patrícia Koehler-Santos; Roberto Giugliani; Patricia Ashton-Prolla
Journal:  Hered Cancer Clin Pract       Date:  2011-12-20       Impact factor: 2.857

5.  BRCA1 and BRCA2 rearrangements in Brazilian individuals with Hereditary Breast and Ovarian Cancer Syndrome.

Authors:  Ingrid Petroni Ewald; Silvia Liliana Cossio; Edenir Inez Palmero; Manuela Pinheiro; Ivana Lucia de Oliveira Nascimento; Taisa Manuela Bonfim Machado; Kiyoko Abe Sandes; Betânia Toralles; Bernardo Garicochea; Patricia Izetti; Maria Luiza Saraiva Pereira; Hugo Bock; Fernando Regla Vargas; Miguel Ângelo Martins Moreira; Ana Peixoto; Manuel R Teixeira; Patricia Ashton-Prolla
Journal:  Genet Mol Biol       Date:  2016 Apr-Jun       Impact factor: 1.771

6.  Genetic predisposition and prediction protocol for epithelial neoplasms in disease-free individuals: A systematic review.

Authors:  J Gowthami; N Gururaj; V Mahalakshmi; R Sathya; T R Sabarinath; Daffney Mano Doss
Journal:  J Oral Maxillofac Pathol       Date:  2020-09-09

Review 7.  Hereditary breast cancer: the era of new susceptibility genes.

Authors:  Paraskevi Apostolou; Florentia Fostira
Journal:  Biomed Res Int       Date:  2013-03-21       Impact factor: 3.411

8.  Evaluation of the need for routine clinical testing of PALB2 c.1592delT mutation in BRCA negative Northern Finnish breast cancer families.

Authors:  Maria Haanpää; Katri Pylkäs; Jukka S Moilanen; Robert Winqvist
Journal:  BMC Med Genet       Date:  2013-08-13       Impact factor: 2.103

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.